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Introduction
Acute upper gastrointestinal hemorrhage remains one of the
most common emergencies in internal medicine. The incidence
rate of upper gastrointestinal bleeding is between 40 and 150
cases per 100.000 [1, 2]. Peptic ulcer bleeding (PUB) is still the
most common bleeding source and responsible for 40% to 50%
of all acute upper gastrointestinal bleeding episodes [1, 3]. In-
ternationally accepted treatment standards and guidelines re-
commend early use of endoscopic therapy and proton pump in-
hibitors [4–6]. However, about 8% to 15% of all patients have
persistent or recurrent bleeding and the mortality rate for PUB
still remains between 10% to 14% [3, 7].
The over-the-scope-clip (OTSC) has been introduced as a
new treatment option and in a recent prospective randomized
study, Schmidt et al showed that use of the device is superior to
conventional endoscopic treatment in recurrent PUB (second-
ary-OTSC) [8]. Until now it was unclear if the OTSC could be as
helpful in first-line treatment of PUB (primary-OTSC). In our
study, we compared primary-OTSC with secondary-OTSC in
Over-the-scope clip in peptic ulcer bleeding: clinical success in
primary and secondary treatment and factors associated with
treatment failure
Authors
Stefan Gölder1, Lukas Neuhas2, Denis Freuer3, Andreas Probst1, Alanna Ebigbo1, Georg Braun1, Juliane Brueckner2,
Johannes Stueckle2, Alexander Meier2, Helmut Messmann1
Institutions
1 University Hospital Augsburg, Department of Internal
Medicine III, Augsburg, Germany
2 Klinikum Dritter Orden, Department of Internal
Medicine I, Munich, Germany
3 Chair of Epidemiology of the LMU Munich at UNIKA-T,
Augsburg, Germany
submitted 9.11.2018
accepted after revision 25.3.2019
Bibliography
DOI https://doi.org/10.1055/a-0898-3357 |
Endoscopy International Open 2019; 07: E846–E854
© Georg Thieme Verlag KG Stuttgart · New York
eISSN 2196-9736
Corresponding author
Dr. Stefan Karl Gölder, University Hospital Augsburg –





Background and study aims It is unclear if the clinical
success rate of the over-the-scope-clip (OTSC) in peptic ul-
cer bleeding (PUB) is comparable when it is used in the first-
or in the second-line of treatment.
Patients and methods Data on endoscopic treatment
(first- vs. second-line) in PUB with OTSC and clinical data
were analyzed. The primary outcome was the clinical suc-
cess of hemostasis, defined as the absence of recurrent
bleeding or further intervention. Secondary outcomes
were factors associated with OTSC failure.
Results From April 2014 to March 2018, 100 patients (age
72 [20–98] y, female 36%) with PUB in the stomach or the
duodenum were treated endoscopically with the OTSC. The
OTSC was used as a first-line procedure (primary-OTSC) in
66 pts. Successful hemostasis could be achieved in 90.9%.
After failure of an initial endoscopic treatment, 34 patients
were treated with the OTSC (secondary-OTSC) and the
treatment was successful in 94.1%. Recurrent bleeding oc-
curred in n=10 for primary-OTSC (16.7%) and in n=7 pts in
the secondary-OTSC (21.9%) (P=0.81). Clinical success in
the primary-OTSC was 75.8% and 73.5% in the secondary-
OTSC respectively.
Conclusions The OTSC has a high rate of initial bleeding
control in first- and second line treatment of PUB. OTSC fail-
ure occurs more often in the duodenum than in the stom-
ach and results in longer intensive care unit stay, higher
amount of transfusions, and a higher reimbursement per
case.
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PUB with regard to persistent or recurrent bleeding as well as
the clinical success of OTSC treatment in the primary and sec-
ondary line of treatment.
Patients and methods
Data for this evaluation were collected prospectively in an
endoscopic database (Viewpoint Version 5.6, GE Healthcare
GmbH, Solingen Germany). We extracted all information on
use of OTSC for PUB. Before and after endoscopic treatment,
clinical data for the patient cohort were recorded (▶Table 1).
Onset of bleeding, patient symptoms, baseline hemoglobin
(g/L), blood-urea-nitrogen (BUN, mg/dL) and lactate (mmol/L)
were documented, if available.
Prior to endoscopy, all patients received an 80-mg intrave-
nous bolus of pantoprazole. Treatment was continued at a
dose of 80mg daily for at least 72 hours. Blood transfusion was
initiated in case of Hb value <70g/L, hemodynamic instability
as well as persistent bleeding. Patients with hemodynamic in-
stability were admitted to the intensive care unit (ICU). Length
of ICU stay was also recorded.
The procedures were performed by experienced endos-
copists in a 24/7 on-call service. We recorded the numbers of
OTSC procedures performed by each endoscopist. To evaluate
endoscopist performance relative to his/her experience, three
groups were created, depending on the number of clips applied
(1–5 OTSC; 5–20 OTSC and >20 OTSC).
In cases of active bleeding or a visible vessel, the OTSC was
applied using a therapeutic endoscope (GIF HQ190, Olympus-
Europe, Hamburg, Germany). The suction method was used in
all cases. All interventions were performed with the 12-mm
type-t clip mounted on a 6-mm cap (Ovesco Endoscopy AG, Tü-
bingen, Germany) and were performed under either general
anesthesia or midazolam/propofol sedation. Depending on the
clinical situation and the endoscopic presentation, one or two
clips were placed to control bleeding.
Furthermore, ulcer size (in millimeters), Forrest classifica-
tion and location (stomach or duodenum) of the target lesion
were documented.
Primary OTSC treatment was defined as endoscopic treat-
ment without any prior endoscopic hemostatic approach. Sec-
ondary OTSC treatment was defined as rescue OTSC-therapy
within 30 days after failed initial endoscopic hemostasis with
injection therapy (adrenalin and/or fibrin glue), through-the-
scope hemoclips (TTS) or a combination of injection and clip
therapy (▶Fig. 1).
The primary outcome was defined as successful initial hemo-
stasis with no recurrent bleeding or further surgical, radiologi-
cal or endoscopic treatment required.
Persistent bleeding was defined as immediate failure of
endoscopic treatment proven by ongoing bleeding (oozing or
squirting) after endoscopic hemostasis.
Recurrent bleeding was diagnosed if a retreatment of the
target lesion was required after initial successful endoscopic
treatment. Repeat endoscopy was performed if clinical symp-
toms of rebleeding occurred (hematemesis or recurrence of
▶ Table 1 Baseline Characteristics of n =100 patients with peptic
gastric or duodenal ulcer bleeding (PUB) and treatment with the over-
the-scope cClip (OTSC).
Median (IQR), N, (%)
Age1 76 (62.75; 83)















RockallScore 7 (6; 8)
Glasgow Blatchford Score (GBS) 16 (14; 17)
Ulcer size (mm) 20 (15; 30)
Ulcer location
▪ Stomach proximal (Fundus/Corpus) 12
▪ Stomach distal (Antrum) 13
▪ Duodenal Bulb 25
▪ Duodenum posterior wall 30
▪ Duodenum anterior wall 17
▪ Duodenum distal 3
Forrestclassification of the lesions
▪ Ia (n) 51
▪ Ib (n) 23
▪ IIa (n) 26
Primary- versus secondary-OTSC
▪ Primary-OTSC (n) 66
▪ Secondary-OTSC (n) 34
Clinical success
▪ Yes 75 (75%)
▪ No 25 (25%)
Bleeding-related mortality
▪ Yes 9 (9%)
▪ No 91
IQR, interquartile range; TTS, through-the-scope clips; OTSC, over the scope
clips; ICU, intensive care unit; NSAIDs, nonsteroidal antiinflammatory drugs.
1 Mean (interquartile range)
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melena) or the patient developed signs of hemodynamic shock
(tachycardia or hypotension).
A “second-look endoscopy” was not performed routinely if
initial clip placement and hemostasis were deemed successful.
Secondary outcomes were clinical risk factors potentially
associated with OTSC failure. We evaluated the location of
bleeding onset (new admission versus in-patient bleeding),
presence of anticoagulation treatment, use of nonsteroidal
anti-inflammatory drugs (NSAIDs), Rockall Score, Glasgow
Blatchford Score (GBS), baseline hemoglobin (g/L), blood urea
nitrogen (BUN mg/dL), Lactate (mmol/L), baseline red blood
cell transfusions, ulcer location (stomach versus duodenum),
Forrest classification of the lesion as well as ulcer size (cm).
After discharge from the hospital, the patient clinical com-
plexity level (PCCL), reimbursement in Euros, length of time in
the intensive care unit (ICU days) and the Case Mix Index (CMI)
of the German Diagnosis Related Groups (G-DRG), a measure of
the financial investment in each individual case, was evaluated.
Mortality in the patient cohort was also documented. Bleed-
ing-related mortality (BRM) was compared to clinical success of
the OTSC treatment. We defined BRM as mortality from either
clinical failure or events of rebleeding.
The data were collected and evaluated using Microsoft Excel
2008 for Mac, SPSS for Mac (Version 25.0 Armonk, IBM Corp.
New York, United States) and R (Version 3.4.4).
Categorical variables were summarized by absolute percen-
tages and continuous variables by median and 95 interquartile
range (IQR).
Differences were evaluated by Fisher’s exact or the Pear-
son’s Chi-square test. In quantitative values, differences were
measured using the Wilcoxon Rank test.
A P value <0.05 was considered statistically significant.
Multivariate logistic regression analysis with a forward step-
wise selection strategy using a likelihood ratio, including the re-
port of relative risks and their 95%CIs, was used to identify in-
dependent risk factors for failure of bleeding control.
This study was conducted in accordance with the ethical
principles of the Declaration of Helsinki, in compliance with
good clinical practice and according to local regulations. All pa-
tients gave written informed consent to the endotherapy. The
study was not supported financially or otherwise by any exter-
nal source.
Results
From April 2014 to March 2018, 100 patients (mean age 76
[20–98] years, female 36%, male 64%) with PUB in the stom-
ach or duodenum were treated endoscopically with the OTSC
Clip in the Department of Internal Medicine III at the University
Hospital Augsburg, Germany.
Primary vs. secondary OTSC
The OTSC was used as a first-line procedure (Primary-OTSC) in
66 patients. Initial bleeding control was achieved in 90.9%
(▶Fig. 1), six of these patients (9.1%) suffered from persistent
bleeding after technically successful OTSC placement in five
cases. Subsequent salvage therapy with angiographic oblitera-
tion (4 cases) or surgery (2 cases) was performed.
After successful angiographic obliteration, two patients
refused further treatment and died in a palliative situation
(3.0%).
Primary OTSC
n = 66 
F1 Ia 35 (52.3 %)
F Ib 12 (18.5 %)
F IIa 19 (29.2 %)
Persistent bleeding
n = 6 (9.1 %)
Op2 n = 2
Angio3 n = 4 with 
n = 2 BRM4 palliativ 
OTSC in n = 100 patients with PUB
Recurrent bleeding
N = 10 (16.7 %)
n = 3 Early (< 24h) vs. 
n = 7 late (2 – 5 d) 
EndoTx5 n = 4 with  
BRM palliativ n = 1
Angio n = 3
EndoTx + Angio n = 1
EndoTx + OP = 1
BRM palliativ n = 1
Recurrent bleeding
n = 7 (21.9 %)
n = 2 early (< 24 h) vs. 
n = 5 late (4 – 12 d)
EndoTx n = 2
Angio n = 1
EndoTx + Angio n = 3
EndoTx + Angio 
+ Op n = 1
BRM palliativ n = 1
Successful hemostasis
n = 60 (90.9 %)
Successful hemostasis
n = 32 (94.1 %)
Clinical success
n = 50 (75.8 %)
Clinical success 
n = 25 (73.5 %)
Secondary OTSC
n = 34
F Ia 16 (48.6 %)
F Ib 11 (31.4 %)
F IIa 7 (20 %) 
Persistent bleeding 
n = 2 (5.9 %)
Angio n = 2 with 
n = 1 BRM palliativ
▶ Fig. 1 Flowchart of the OTSC (over-the-scope-clip) treatment in
n=100 patients with peptic ulcer bleeding (PUB). Primary-OTSC
treatment was when no other endoscopic hemostatic approach
had been performed. Secondary-OTSC was a rescue OTSC-therapy
after failed initial endoscopic hemostasis with the combination of
injection therapy and through-the-scope clips (TTS). Persistent
bleeding was when the bleeding source could not be controlled by
endoscopic treatment alone. If initial endoscopic OTSC treatment
(primary-OTSC or secondary-OTSC) could stop the bleeding, the
case was counted as successful hemostasis. Recurrent bleeding
was detected by clinical presentation or endoscopy and further
therapy initiated. If no other treatment modality was necessary
besides the OTSC application, the case was classified as clinical
success with OTSC treatment.
1 F = Forrest stage of the ulcer
2 OP=operative treament of the bleeding site
3 Angio = angiographic treatment of the bleeding
4 BRM=Bleeding related mortality
5 EndoTx= Endoscopic therapy
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▶ Table 2 Characteristics of the patients with primary- or secondary-OTSC treatment.
Primary OTSC Secondary OTSC P
n=66 n=34
Age1 77 (67; 83) 71 (61; 81) 0.32
Patient clinical complexity level (PCCL)1 3 (1; 4) 3 (2; 4) 0.88
Gender 1
▪ male 42 (0.64) 22 (0.65)
▪ female 24 (0.36) 12 (0.35)
Outpatient bleed 37 (0.56) 20 (0.59) 0.83
Inpatient bleed 29 (0.44) 14 (0.41)
Anticoagulation 0.37
▪ None 33 (0.5) 23 (0.68)
▪ ASS mono 6 (0.09) 2 (0.06)
▪ NOAK 7 (0.11) 1 (0.03)
▪ combinations 20 (0.30) 8 (0.24)
NSAIDs 0.48
▪ No 31 (0.74) 18 (0.69)
▪ Yes 9 (0.21) 8 (0.31)
▪ Unclear 2 (0.05) 0 (0)
ICU (d)1 3 (2; 5) 4 (3; 7.25) 0.05
Rockall Score1 7 (6; 8) 7 (6; 8.75) 0.52
Glasgow Blatchford Score (GBS)1 16 (14; 17) 15 (12.5; 16) 0.14
Baseline hemoglobin (g/L)1 68 (58; 76) 66 (56.5; 73.75) 0.42
BUN (mg/dL)1 89.5 (66; 116) 82.5 (49.75; 118.5) 0.47
Lactate (mmol/l)1 2.5 (1.1; 4.5) 5.25 (2.58; 7.18) 0.07
Baseline red cell transfusions1 3 (2; 4) 4 (3; 7) 0.06
Case mix Index1 2.149 (1.16; 3.60) 2.37 (1.41; 3.56) 0.3
Reimbursement (Euro)1 7217 (3874; 11985) 7835.5 (4597; 11836.25) 0.38
Ulcer size (cm)1 2 (1.5; 3) 2 (1.5; 3) 0.61
Location of the ulcer 1
stomach 17 (0.26) 8 (0.24)
duodenum 49 (0.74) 26 (0.77)
Forrest 0.26
Ia (n; rel. %) 35 (0.53) 16 (0.47)
Ib 12 (0.18) 11 (0.32)
IIa 19 (0.29) 7 (0.21)
Technical success 1
yes (rel. %) 65 (0.99) 34 (1)
no 1 (0.015) 0 (0)
Clinical success 0.81
yes (rel. %) 50 (0.76) 25 (0.74)
no 16 (0.24) 9 (0.27)
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The OTSC was used as a second-line procedure (secondary-
OTSC) for reactivated bleeding after successful initial endo-
scopic hemostasis with injection of adrenalin (mean 15mL
range: 5–50mL) or fibrin glue (mean 2mL range: 1–4mL). For
mechanical bleeding control, only treatment with TTS (mean 4
range 1–12) was allowed in this study. In this group the bleed-
ing source showed active bleeding (Forrest Ia or Ib) in n =27
cases. In seven cases a non-bleeding visible vessel was found
(Forrest IIa). Two patients suffered from persistent bleeding
(5.9%) after OTSC treatment. Both patients underwent angio-
graphic obliteration of the feeding vessel. One patient refused
further treatment and died in palliative care (2.9%).
Successful hemostasis with secondary-OTSC was achieved in
94.1%. Persistent bleeding after OTSC treatment occurred in
8% of all cases (primary- and secondary-OTSC).
Recurrent bleeding occurred 1 to 12 days after successful in-
itial treatment, (median 3.5 d) in 16.7% (N=10) after primary-
OTSC and 21.9% (N=7) after secondary-OTSC treatment (P=
0.81).
In the primary-OTSC group, ten patients (16.7%) suffered an
early recurrent bleeding (< 24 hours, n =3) or had late recurrent
bleeding (> 24 hours range 2–5 days, n =7). In four patients, a
second endoscopic treatment was successful but one patient
died in a palliative situation after successful bleeding control.
Four patients received angiography and one surgery for bleed-
ing control. One patient developed symptoms of recurrent
bleeding but a reintervention was denied because of comorbid-
ities and the patient’s age (90 years).
In the secondary-OTSC group, seven patients (21.2%) devel-
oped early rebleeding (< 24 hours, n =2) or late rebleeding
(> 24 hours range 4–12 days, n =5). Successful endoscopic
treatment was achieved in two patients and five patients were
treated with angiographic obliteration. One patient underwent
surgery (▶Fig. 1).
Recurrent bleeding occurred in 17% of all cases (primary-
and secondary-OTSC).
The overall clinical success for OTSC in the primary-OTSC
group was 75.8% versus 73.5% in the secondary-OTSC group
(P=0,81) (▶Fig. 1 and ▶Table 1).
Factors associated with OTSC failure
In the group of patients with persistent or recurrent bleeding
we found no differences in risk stratification scores (Rockall
and Glasgow Blatchford Socre), baseline hemoglobin, BUN or
lactate. Also, no differences in the frequency of antiplatelet or
anticoagulant drugs or NSAID use. There were no differences
between new admission- or inpatient bleeders (▶Table 2).
The mean amount of packed red blood cells transfused in
the OTSC failure group was higher (4 versus 3, P= 0,01) and ul-
cer size was larger (30 versus 20mm, P=0.07).
Duration of ICU treatment was longer (4 versus 3 days, P=
0.02). Reimbursement per case for the treatment failure group
was higher from those successfully treated with OTSC (10055
Euro versus 6155 Euro P=0.04) (CMI 3.036 versus 1.892 P=
0.04). The trend showed a higher reimbursement and CMI in
case of treatment escalation with operation or angiographic in-
tervention.
The proportion of active oozing (Forrest Ib 23%) or spurting
(Forrest Ia 51%) bleeding ulcers was 74% (▶Fig. 1, ▶Fig. 2) in
the entire study cohort. A visible vessel (Forrest IIa) was found
in 26% of ulcers (▶Fig. 3). We found a slightly higher rate of ul-
cers with a visible vessel (Forrest IIa) in the primary-OTSC group
(29.2% vs. 20.6% P=0,26).
Treatment success was independent of Forrest stage of the
ulcer (P=0.26).
Endoscopic treatment was performed by 15 different physi-
cians in our institution. To evaluate the grade of experience
with the OTSC system in an active bleeding situation, we ana-
lyzed three groups: fewer than 5 OTSC applications, five to 20
or more than 20 clip applications (▶Table 3). We found no
difference in the bleeding control rate among the groups
(P=0,58). Interestingly, we had a higher rate of OTSC-un-
experienced physicians (<5 OTSC) in the primary-OTSC group
(28.8%) than in the middle group (5–20) 7.6% (P= 0.02). The
▶ Table 2 (Continuation)





<5 19 (0.29) 3 (0.09)
5–20 5 (0.08) 8 (0.24)
> 20 42 (0.64) 23 (0.68)
Bleeding-related mortality 1
Yes 6 (0.09) 3 (0.09)
No 60 (0.91) 31 (0.91)
IQR, interquartile range; TTS, through-the-scope clips; OTSC, over-the-scope clips; ICU, intensive care unit; NSAIDs, nonsteroidal antiinflammatory drugs.
1 Mean (interquartile range)
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most experienced physicians had comparable applications in
the primary- or secondary-OTSC group (63.6% versus 67.7%).
Logistic regression for clinical failure identified ulcer size and
location in the duodenum, especially at the posterior duodenal
wall, as factors associated with a higher rate of treatment fail-
ure (▶Table 4). Also, the transfusion requirement was higher in
the treatment failure group.
Bleeding-related mortality
The rate of BRM was 6% (6 patients). In case of failure of clini-
cally successful OTSC treatment (n =3), all patients received an-
giographic bleeding control, but died due to prolonged hemor-
rhagic shock.
In case of recurrent bleeding, the bleeding source could be
controlled by endoscopic treatment but the patient denied
any further therapy.
Three patients (3%) in the successful hemostasis group also
died due to prolonged hemorrhagic shock but showed no
symptoms of recurrent bleeding and were also classified as
BRM.
Seven patients (7%) died for reasons other than intestinal
bleeding (sepsis 5×, decompensated liver cirrhosis, cardiore-
spiratory failure).
BRM occurred more often in the uncontrolled bleeding
group (3 vs. 6 patients P=0.007), but we found no difference
between the primary-OTSC versus secondary OTSC group (6%
in both groups, ▶Fig. 1, ▶Table 1, ▶Table2).
Discussion
Our study shows that the primary-OTSC for first-line treatment
of PUB has a comparably high rate of initial bleeding control
with secondary-OTSC (90.9% versus 94.1%). Nevertheless, in
the primary-OTSC group, we found a higher rate of salvage
therapy (angiographic or surgery) of 9.1% compared to 5.9%
in the secondary-OTSC group. This in part could be due to the
fact that we had a per group higher rate of Forrest Ia (spurting)
bleedings 53% versus 47% (P=0.26) in the secondary-OTSC
group. Forrest Ia ulcers have a higher per lesion rate of persist-
ent and recurrent bleeding [9].
After successful initial treatment with the OTSC, recurrent
bleeding occurred more often in the secondary-OTSC group
than in the primary-OTSC group (21.9% vs 16.7%). This could
be explained by the efficiency of the OTSC clip itself. This device
has a higher compression force and therefore, obliteration of
the feeding vessel is higher than with conventional TTS Clips.
We also found more visible vessels (Forrest IIa) in the primary-
OTSC (29.2%) compared to the secondary-OTSC group (20%)
(P=0.26). In the secondary-OTSC we might have a selection of
more difficult-to-treat bleeding lesions. Therefore, a higher
rate of recurrence may be explained. We also found that two re-
current bleeds occurred 8 and 12 days after the initial OTSC
treatment. In one patient the clip was still in position and in
one patient the clip had dislodged completely from the ulcer.
In the first prospective randomized trial comparing the OTSC
as second-line therapy with conventional endoscopic retreat-
ment, Schmidt et al. found 6.1% rate of persistent bleeding
and a 9.1% rate of recurrent bleeding compared to 42.2% per-
sistent bleeding and 16.1% recurrent bleeding for conventional
endoscopic treatment. This defined the OTSC as the new stand-
▶ Fig. 2 Primary-OTSC. a Forrest Ia bleeding in the stomach diag-
nosed during emergency endoscopy. b An OTSC mounted on the
therapeutic endoscope was successfully placed on the bleeding
site. c, d After initial bleeding control and in the control endos-
copy after 3 days, the clip was found in position.
▶ Fig. 3 Secondary-OTSC. a Large ulcer with a central vessel. Prior
to examination, TTS clips had been placed. b Because of recurrent
bleeding, the TTS clips were removed. c An OTSC was placed on
the central vessel. d In the second-look endoscopy the vessel was
successfully closed by the OTSC.
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▶ Table 3 Factors associated with clinical failure in OTSC treatment for peptic ulcer bleeding.
Clinical success with OTSC treatment
Yes n=75 No n=25 P
Age1 76 (62.5; 83) 72 (65; 83) 0.96
Patient Clinical Complexity Level (PCCL)1 3 (1; 4) 4 (2; 4) 0.08
Gender 0.16
▪ male 51 (0.68) 13 (0.52)
▪ female 24 (0.32) 12 (0.48)
Outpatient bleed 42 (0.56) 15 (0.6) 0.82
Inpatient bleed 33 (0.44) 10 (0.4)
Anticoagulation 0.34
▪ None 40 (0.53) 16 (0.64)
▪ ASS mono 8 (0.11) 0 (0)
▪ NOAC 7 (0.09) 1 (0.04)
▪ others (Combination) 20 (0.27) 8 (0.32)
NSAIDs 0.76
▪ No 36 (0.735) 13 (0.684)
▪ Yes 12 (0.245) 5 (0.263)
▪ Unclear 1 (0.02) 1 (0.053)
ICU (d)1 3 (2; 6) 4 (3; 9) 0.02
Rockall Score1 7 (6; 8) 8 (6; 9) 0.15
Glasgow Blatchford Score (GBS)1 15 (14; 17) 16 (15; 18) 0.10
Baseline hemoglobin (g/L)1 67 (57; 74.5) 70 (58; 75) 0.51
BUN (mg/dL)1 87 (57; 118) 92 (75; 116) 0.44
Lactate (mmol/l)1 2.6 (1.38; 6.8) 4.1 (2.582; 8.5) 0.23
Baseline red cell transfusions1 3 (2; 4) 4 (3; 9) 0.01
Case mix Index1 1.892 (1.19; 3.37) 3.036 (1.804; 4.683) 0.04
Reimbursement (Euro)1 6155 (3904.5; 11125) 10055 (6044; 15690) 0.04
Ulcer size (cm)1 2 (1; 3) 3 (2; 3) 0.07
Location of the ulcer
▪ Stomach proximal (Fundus/Corpus) 10 (0.13) 2 (0.08) 0.05
▪ Stomach distal (Antrum) 13 (0.17) 0 (0)
▪ Duodenal bulb 19 (0.25) 6 (0.24)
Duodenum posterior wall 17 (0.23) 13 (0.52)
▪ Duodenum anterior wall 13 (0.17) 4 (0.16)
▪ Duodenum distal 3 (0.04) 0 (0)
Forrest 0.26
▪ Ia 35 (0.47) 16 (0.64)
▪ Ib 20 (0.27) 3 (0.12)
▪ IIa 20 (0.27) 6 (0.24)
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ard in endoscopic treatment for recurrent peptic ulcer bleed-
ing.
The clinical success rate of primary- and secondary-OTSC in
our study is almost comparable (75.8% vs. 73.5%).
The clinical success rate of the first prospective randomized
trial by Schmidt et al. found a final success rate of 84.8% for
second-line treatment in PUB. In this study, the rate of Forrest
Ia bleeding was 16.7% in a follow-up period of 30 days after in-
itial bleeding control. Other case series or retrospective studies
found rates of initial bleeding control of 77% to 100% and of re-
bleeding of 7% to 42.8% [10–21].
We evaluated factors that might influence the clinical suc-
cess of endoscopic treatment in PUB [22]. We found that ulcer
location in the duodenum resulted in a higher rate of unsuc-
cessful OTSC treatment. Ulcer size in the treatment failure
group was larger (3 vs. 2 cm) but this did not reach statistical
significance. In logistic regression we found that ulcer location
at the posterior duodenal wall was a factor associated with
OTSC failure (P=0.01). This finding is in accord with the current
literature that could show a higher treatment failure for ulcers
in this location [22, 23].
As a consequence of the more severe clinical scenario of
failed endoscopic hemostasis, we found a longer ICU stay and
a higher rate of red blood cell transfusions.
According to the German reimbursement system (G-DRG),
the case mix index (CMI) and the reimbursement rate were
higher for uncontrolled bleeding. There is only limited data on
the reimbursement rate and cost of failed hemostasis in gastro-
duodenal ulcer bleeding. A study from the United States found
higher cost as well as reimbursement in case of salvage therapy
with angiography or surgery [24].
Also of interest is the finding that we could not identify a dif-
ference in the experience of the endoscopist who applied the
OTSC clip. This is comparable to other studies that showed a
high rate of bleeding control when the OTSC system was used
as the initial treatment modality. But our work is the first to
show this in a real-life setting in a large referral endoscopy unit
with 15 different endoscopists performing the procedure.
We found an overall mortality rate of 16% in our cohort. Sev-
en patients died of reasons unrelated to bleeding and in three
patients, bleeding was controlled but the patients died of pro-
longed hemorrhagic shock. Six patients died due to recurrent
bleeding from the initial source. The overall rate of mortality
was comparable to published data in severe ulcer bleeding and
OTSC treatment of 10% to 18% [8, 12, 21].
There are some limitations to our findings. This is a retro-
spective evaluation of prospectively collected data, which did
not compare OTSC treatment to conventional endoscopic he-
mostasis. Patient recruitment was performed within a time
period of 4 years. Patient allocation to a treatment arm was
▶ Table 3 (Continuation)
Clinical success with OTSC treatment
Yes n=75 No n=25 P
Primary vs. Secondary OTSC 0.81
▪ Primary OTSC 50 (0.67) 16 (0.64)
▪ Secondary OTSC 25 (0.33) 9 (0.36)
Primary treatment (w/o) OTSC 0.28
▪ Adrenalin + TTS 8 (0.33) 5 (0.46)
▪ Adrenalin + TTS + Fibrin Clue 13 (0.54) 3 (0.27)
▪ Fibrin Clue 3 (0.13) 2 (0.18)
▪ OTSC in recurrent Primary-OTSC 0 (0) 1 (0.09)
Frequency of OTSC Applications/doctor 0.58
▪ <5 15 (0.2) 7 (0.28)
▪ 5–20 11 (0.15) 2 (0.08)
▪ >20 49 (0.65) 16 (0.64)
▶ Table 4 Logistic regression for factors associated with clinical failure
in OTSC treatment for peptic ulcer bleeding.
Factors OR (CI) P value
ICU (d) 1.04 (0.97 –1.12) 0.30
Baseline red cell transfusion 1.31 (1.13 –1.57) 0.01
Stomach vs. duodenum 4.96 (1.30 –32.74) 0.04
Duodenum posterior wall 8.11 (1.89 –56.94) 0.01
Ulcer size (≥1.5 cm) 7.19 (1.31 –134.49) 0.07
Anticoagulation 0.64 (0.23–1.79) 0.40
Models were adjusted for sex and age
ICU, intensive care unit; OR, odds ratio; CI, confidence interval.
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based on the character of the bleeding (initial versus recurrent
bleeding) which could be a source of potential bias.
Recent studies show that endoscopic doppler examination
of the ulcer base could direct the endoscopic therapy, this was
not performed during our study [25, 26].
Conclusion
In conclusion, the OTSC has a high rate of initial bleeding con-
trol in first- and second line treatment for PUB. The rate of re-
current bleeding was lower in first- than in second-line treat-
ment in our study. Location of the bleeding source and ulcer
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